Follistatin 344
Research Goal: Evaluate the suppression of myostatin (GDF-8) to facilitate rapid skeletal muscle cell proliferation and lean mass accrual.
Route
Subcutaneous injection
Dose range
100 mcg
Frequency
Typically administered in short, high-frequency pulses
Cycle length
10–20 days per cycle, followed by a 4-week washout
Overview
Research Goal: Evaluate the suppression of myostatin (GDF-8) to facilitate rapid skeletal muscle cell proliferation and lean mass accrual.
Preparation: Reconstitute with 1.0 mL sterile water or bacteriostatic water. Gently swirl; do not shake.
Studied benefits
- Similar to Follistatin 315, it acts as a myostatin inhibitor but is often noted for its localized action and slightly different binding affinity
- It supports significant muscle hypertrophy and has been researched for its potential to improve hair growth
Reported side effects
- Generally similar to the 315 variant, including potential muscle stiffness or soreness
- Human clinical safety data is limited
Protocol
Dosing Schedule (Subcutaneous/Intramuscular)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Phase | Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Blast Protocol | 100 mcg | 4 units (0.04 mL) | + Log |
| Standard Research | 100 mcg | 4 units (0.04 mL) | + Log |
Frequency
Typically administered in short, high-frequency pulses.
Timing
Post-workout is preferred in exercise-mimetic research.
Cycle length
10–20 days per cycle, followed by a 4-week washout.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
50 doses of 100 mcg per vial
At the starting dose (100 mcg × 7/week for a 4-week cycle) you would use about 2.8 mg, i.e. 1 × 5 mg vial. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a calorie-surplus, high-protein diet tailored to muscle protein synthesis to support the increased demands of myostatin suppression. Incorporate heavy resistance training and periodization to maximize the growth stimulus and ensure that the additional muscle mass is balanced across the physique. Ensure 7–9 hours of quality sleep to facilitate the intense tissue repair and anabolic signaling triggered by the peptide. Maintain optimal hydration and consider joint-support supplements, as the rapid increase in muscle size and strength can place heightened stress on the skeletal and ligamentous systems.
Evidence
Research summaries
Long-Term Enhancement of Skeletal Muscle Mass and Strength by Follistatin-344
Findings: Provides long-lasting muscle growth (over 2 years), safe for the heart, and avoids reproductive side effects.
Follistatin 344 (FS-344) is actually the "blueprint" version used in gene therapy. When injected, the body reads this blueprint and turns it into the circulating protein (FS-315). In a major study on monkeys, a single treatment with FS-344 led to muscle growth that lasted for over 15 months! The animals got stronger and bigger without any negative effects on their heart or ability to have babies (which was a risk with other versions). This study is famous because it showed that FS-344 is the safest, most reliable way to produce sustained muscle growth for treating diseases like muscular dystrophy. It’s like installing a permanent software update that tells your muscles to keep growing.
Read the study ↗Follistatin Gene Therapy for Sporadic Inclusion Body Myositis
Findings: Improves walking distance in patients with muscle disease, safe for human use, prevents muscle wasting.
This was a groundbreaking human trial. Six patients with a muscle-wasting disease (IBM) received injections of Follistatin 344 gene therapy into their leg muscles. The goal was to stop their legs from getting weaker. The results showed that the treatment was safe and effectively improved the distance they could walk in a 6-minute test. Some patients even saw their muscle strength stabilize instead of getting worse. This proves that the science seen in mice translates to real people. By using FS-344, the doctors could target specific muscles (like the quads) to save them from wasting away, offering hope for conditions that currently have no cure.
Read the study ↗Increasing Lean Muscle Mass via Nanoparticle-Mediated Delivery of FS-344 mRNA
Findings: Burns fat while building muscle, reduces "bad" fat tissue, and works without using viruses.
Most gene therapies use a virus to deliver the message, which can be scary. This study used "nanoparticles" (tiny fat bubbles) to deliver the FS-344 message instead. It worked perfectly: the liver read the message and pumped out Follistatin for 3 days. The result? The mice built muscle and, surprisingly, lost a significant amount of body fat. The Follistatin blocked myostatin (which stops muscle) and activin A (which promotes fat). This dual-action of "more muscle, less fat" makes FS-344 a prime candidate not just for disease, but for combating obesity and frailty in older adults.
Read the study ↗More references (5)
- Follistatin-344: A Multifaceted Agent in Research Investigations, 2024
- AAV1-FS344 Gene Therapy for Becker Muscular Dystrophy (Phase I/II), 2015
- Myostatin Inhibition by Follistatin 344 in Duchenne Muscular Dystrophy Models, 2013
- Long-term Safety of Follistatin 344 Gene Transfer, 2010
- The Isoforms of Follistatin and Their Roles in Muscle Growth, 2008
Identification
Chemistry
- cas
- 80449-31-6 (primary); 100043-71-8 (alternate); 129954-34-3 (supplier variants)
- formula
- Varies by source: C₁₃₅₀H₂₁₅₃N₄₀₅O₄₃₃S₃₉ (some suppliers); C₈₅₂H₁₃₄₇N₂₂₉O₂₅₅S₆ (others); C₂₀₃H₃₁₇N₅₅O₆₄S₁ (alternate)
- molecular weight
- Approximately 37-40 kDa (typically ~39 kDa for glycosylated recombinant form); 3780 g/mol reported by some suppliers for alternative calculations
- sequence
- 344 amino acid precursor protein (full-length); mature FS315 sequence 315 amino acids after signal peptide removal; contains the distinctive 27-amino acid acidic C-terminal tail (unique to FS344-derived FS315 isoform)
- source
- Natural; generated through alternative splicing of FST gene; recombinant forms produced in HEK293 cells or other expression systems
- biosynthesis
- Ribosomal; produced from mRNA transcripts generated by alternative splicing; recombinant forms engineered in mammalian cells
- type
- Monomeric glycoprotein; contains multiple disulfide bonds; heavily post-translationally glycosylated
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
BPC-157, TB-500
- Route
- Subcutaneous
- Dose
- 333 mcg – 667 mcg
- Cycle
- 8–12 weeks
CJC-1295 (No DAC)
No DAC
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 8–12 weeks